ALX 1393

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 531438

CAS#: 949164-09-4

Description: ALX 1393 is a glycine transporter-2 inhibitor.


Chemical Structure

img
ALX 1393
CAS# 949164-09-4

Theoretical Analysis

MedKoo Cat#: 531438
Name: ALX 1393
CAS#: 949164-09-4
Chemical Formula: C23H22FNO4
Exact Mass: 395.1533
Molecular Weight: 395.4304
Elemental Analysis: C, 69.86; H, 5.61; F, 4.80; N, 3.54; O, 16.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: ALX 1393

IUPAC/Chemical Name: (2S)-2-amino-3-{[2-(benzyloxy)phenyl](3-fluorophenyl)methoxy}propanoic acid

InChi Key: ADUSZEGHFWRTQS-AIBWNMTMSA-N

InChi Code: InChI=1S/C23H22FNO4/c24-18-10-6-9-17(13-18)22(29-15-20(25)23(26)27)19-11-4-5-12-21(19)28-14-16-7-2-1-3-8-16/h1-13,20,22H,14-15,25H2,(H,26,27)/t20-,22?/m0/s1

SMILES Code: O=C(O)[C@@H](N)COC(C1=CC=CC=C1OCC2=CC=CC=C2)C3=CC=CC(F)=C3

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 395.4304 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Takahashi Y, Hara K, Haranishi Y, Terada T, Obara G, Sata T. Antinociceptive effect of intracerebroventricular administration of glycine transporter-2 inhibitor ALX1393 in rat models of inflammatory and neuropathic pain. Pharmacol Biochem Behav. 2015 Mar;130:46-52. doi: 10.1016/j.pbb.2015.01.001. PubMed PMID: 25579325.

2: Motoyama N, Morita K, Shiraishi S, Kitayama T, Kanematsu T, Uezono Y, Dohi T. Relief of cancer pain by glycine transporter inhibitors. Anesth Analg. 2014 Oct;119(4):988-95. doi: 10.1213/ANE.0000000000000388. PubMed PMID: 25076101.

3: Barthel F, Urban A, Schlösser L, Eulenburg V, Werdehausen R, Brandenburger T, Aragon C, Bauer I, Hermanns H. Long-term application of glycine transporter inhibitors acts antineuropathic and modulates spinal N-methyl-D-aspartate receptor subunit NR-1 expression in rats. Anesthesiology. 2014 Jul;121(1):160-9. doi: 10.1097/ALN.0000000000000203. PubMed PMID: 24598217.

4: Eckle VS, Antkowiak B. ALX 1393 inhibits spontaneous network activity by inducing glycinergic tonic currents in the spinal ventral horn. Neuroscience. 2013 Dec 3;253:165-71. doi: 10.1016/j.neuroscience.2013.08.042. PubMed PMID: 23994185.

5: Mingorance-Le Meur A, Ghisdal P, Mullier B, De Ron P, Downey P, Van Der Perren C, Declercq V, Cornelis S, Famelart M, Van Asperen J, Jnoff E, Courade JP. Reversible inhibition of the glycine transporter GlyT2 circumvents acute toxicity while preserving efficacy in the treatment of pain. Br J Pharmacol. 2013 Nov;170(5):1053-63. doi: 10.1111/bph.12343. PubMed PMID: 23962079; PubMed Central PMCID: PMC3949653.

6: Yoshikawa S, Oguchi T, Funahashi Y, de Groat WC, Yoshimura N. Glycine transporter type 2 (GlyT2) inhibitor ameliorates bladder overactivity and nociceptive behavior in rats. Eur Urol. 2012 Oct;62(4):704-12. doi: 10.1016/j.eururo.2012.01.044. PubMed PMID: 22341128; PubMed Central PMCID: PMC3414688.

7: Nimmervoll B, Denter DG, Sava I, Kilb W, Luhmann HJ. Glycine receptors influence radial migration in the embryonic mouse neocortex. Neuroreport. 2011 Jul 13;22(10):509-13. doi: 10.1097/WNR.0b013e328348aafe. PubMed PMID: 21666516.

8: Jeong HJ, Vandenberg RJ, Vaughan CW. N-arachidonyl-glycine modulates synaptic transmission in superficial dorsal horn. Br J Pharmacol. 2010 Oct;161(4):925-35. doi: 10.1111/j.1476-5381.2010.00935.x. PubMed PMID: 20860669; PubMed Central PMCID: PMC2992905.

9: Nishikawa Y, Sasaki A, Kuraishi Y. Blockade of glycine transporter (GlyT) 2, but not GlyT1, ameliorates dynamic and static mechanical allodynia in mice with herpetic or postherpetic pain. J Pharmacol Sci. 2010;112(3):352-60. PubMed PMID: 20173309.

10: Haranishi Y, Hara K, Terada T, Nakamura S, Sata T. The antinociceptive effect of intrathecal administration of glycine transporter-2 inhibitor ALX1393 in a rat acute pain model. Anesth Analg. 2010 Feb 1;110(2):615-21. doi: 10.1213/ANE.0b013e3181c7ebbb. PubMed PMID: 20081141.

11: Hermanns H, Muth-Selbach U, Williams R, Krug S, Lipfert P, Werdehausen R, Braun S, Bauer I. Differential effects of spinally applied glycine transporter inhibitors on nociception in a rat model of neuropathic pain. Neurosci Lett. 2008 Nov 21;445(3):214-9. doi: 10.1016/j.neulet.2008.09.012. PubMed PMID: 18793697.

12: Micu I, Ridsdale A, Zhang L, Woulfe J, McClintock J, Brantner CA, Andrews SB, Stys PK. Real-time measurement of free Ca2+ changes in CNS myelin by two-photon microscopy. Nat Med. 2007 Jul;13(7):874-9. PubMed PMID: 17603496.

13: Xu TX, Gong N, Xu TL. Inhibitors of GlyT1 and GlyT2 differentially modulate inhibitory transmission. Neuroreport. 2005 Aug 1;16(11):1227-31. PubMed PMID: 16012354.